(Q44643220)

5 December 2017

title

Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters (English)

1 reference

5 December 2017

4

1 reference

5 December 2017

Karin F Wader

1

1 reference

5 December 2017

Unn-Merete Fagerli

2

1 reference

5 December 2017

Randi U Holt

3

1 reference

5 December 2017

Anders Sundan

5

1 reference

5 December 2017

Anders Waage

6

1 reference

5 December 2017

publication date

16 August 2011

1 reference

European Journal of Haematology

5 December 2017

published in

1 reference

5 December 2017

volume

87

1 reference

5 December 2017

issue

5

1 reference

5 December 2017

page(s)

394-399

1 reference

Met, metastasis, motility and more

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

Hepatocyte growth factor promotes migration of human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

Emerging multipotent aspects of hepatocyte growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

Drug development of MET inhibitors: targeting oncogene addiction and expedience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

Targeting the c-Met signaling pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

The Sema domain of Met is necessary for receptor dimerization and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

C-terminal truncated forms of Met, the hepatocyte growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

Suramin modulates cellular levels of hepatocyte growth factor receptor by inducing shedding of a soluble form.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

Vascular origin of a soluble truncated form of the hepatocyte growth factor receptor (c-met).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

c-Met ectodomain shedding rate correlates with malignant potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

Targeting the tumor and its microenvironment by a dual-function decoy Met receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01622.X

10.1111/J.1600-0609.2011.01622.X

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference